However, integrating large amounts of clinical, radiologic, pathologic, and molecular data to develop a treatment plan for patients can be complicated. In recent years there has been an evolution of Molecular Tumor Boards that combine traditional tumor board members with computational biologists, geneticists, and research scientists.

Together, they can better integrate patient and tumor data to develop novel treatment plans by targeting a larger fraction of identified molecular alterations, yielding a higher ‘matching score’, which has been shown to be correlated with significantly improved disease control rates, as well as longer progression-free and overall survival rates, compared to targeting of fewer somatic alterations.

We will discuss how personalized treatment regimens customized combination therapies can be safely and effectively recommended by a Molecular Tumor Board to improve patient survival outcomes.

There is a growing awareness that the interpretation of the NGS results could be highly complex, and if misinterpreted, may lead to undesirable patient outcomes. This necessitates the setup of molecular tumor board (MTB), as an important infrastructure for NGS discussion and treatment recommendations. In this webinar, the essential steps and knowledge involved in navigating the complexity of NGS results would be discussed, and the many important roles of MTB addressed.